Case Report
BibTex RIS Cite

Treatment of Mucormycosis with Liposomal Amphotericin B, Posaconazole and Deferasirox: A Case Report

Year 2016, , 32 - 35, 01.03.2016
https://doi.org/10.5799/jmid.328767

Abstract

In this paper, we present a 69 years old diabetic patient with mucormycosis who was succesfully treated with liposomal
amphotericin B (LAMB), posaconazole and deferasirox despite having no adequate surgery. There was no relapse on
6 month post-treatment follow-up. We conclude that combination of antifungal antibiotics with deferasirox may be
successful in the salvage therapy of mucormycosis especially in diabetic patients. J Microbiol Infect Dis 2016;6(1): 32-35

References

  • 1. Zeka AN, Taşbakan M, Pullukçu H, et al. Evaluation of zygomycosis cases by pooled analysis method reported from Turkey. Mikrobiyol Bul 2013;47:708-716.
  • 2. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41:634-653.
  • 3. Aslan M, Öz Y, Akay MO, Akşit F. Evaluation of febrile neutropenia in hematologic malignancy patients. Mediterr J Infect Microb Antimicrob 2014; 3:20.
  • 4. Özden M, Denk A, Demirdağ K, Elkıran T. Investigation of Febrile Neutropenic Cases and Risk Factors. Mediterr J Infect Microb Antimicrob 2014;2:3.
  • 5. Cornely OA, Arikan-Akdagli S, Dannaoui E, et al. ESCMID and ECMM Joint Clinical Guidelines for the Diagnosis and Management of Mucormycosis 2013. Clin Microbiol Infec 2014; 20 Suppl. 3:5-26.
  • 6. Ibrahim AS, Gebermariam T, Fu Y, et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 2007;117: 2649-2657.
  • 7. Spellberg B, Ibrahim AS, Chin-Hong PV, et al. The Deferasirox–AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother 2012;67:715-722.
  • 8. Frater JL, Hall GS, Procop GW. Histologic features of zygomycosis: emphasis on perineural invasion and fungal morphology. Arch Pathol Lab Med 2001; 125: 375-378.
  • 9. Rüping MJ, Heinz WJ, Kindo AJ, et al. Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother 2010; 65:296-302.
Year 2016, , 32 - 35, 01.03.2016
https://doi.org/10.5799/jmid.328767

Abstract

References

  • 1. Zeka AN, Taşbakan M, Pullukçu H, et al. Evaluation of zygomycosis cases by pooled analysis method reported from Turkey. Mikrobiyol Bul 2013;47:708-716.
  • 2. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41:634-653.
  • 3. Aslan M, Öz Y, Akay MO, Akşit F. Evaluation of febrile neutropenia in hematologic malignancy patients. Mediterr J Infect Microb Antimicrob 2014; 3:20.
  • 4. Özden M, Denk A, Demirdağ K, Elkıran T. Investigation of Febrile Neutropenic Cases and Risk Factors. Mediterr J Infect Microb Antimicrob 2014;2:3.
  • 5. Cornely OA, Arikan-Akdagli S, Dannaoui E, et al. ESCMID and ECMM Joint Clinical Guidelines for the Diagnosis and Management of Mucormycosis 2013. Clin Microbiol Infec 2014; 20 Suppl. 3:5-26.
  • 6. Ibrahim AS, Gebermariam T, Fu Y, et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 2007;117: 2649-2657.
  • 7. Spellberg B, Ibrahim AS, Chin-Hong PV, et al. The Deferasirox–AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother 2012;67:715-722.
  • 8. Frater JL, Hall GS, Procop GW. Histologic features of zygomycosis: emphasis on perineural invasion and fungal morphology. Arch Pathol Lab Med 2001; 125: 375-378.
  • 9. Rüping MJ, Heinz WJ, Kindo AJ, et al. Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother 2010; 65:296-302.
There are 9 citations in total.

Details

Subjects Health Care Administration
Journal Section Case Report
Authors

Uğur Önal This is me

Publication Date March 1, 2016
Published in Issue Year 2016

Cite

APA Önal, U. (2016). Treatment of Mucormycosis with Liposomal Amphotericin B, Posaconazole and Deferasirox: A Case Report. Journal of Microbiology and Infectious Diseases, 6(1), 32-35. https://doi.org/10.5799/jmid.328767
AMA Önal U. Treatment of Mucormycosis with Liposomal Amphotericin B, Posaconazole and Deferasirox: A Case Report. J Microbil Infect Dis. March 2016;6(1):32-35. doi:10.5799/jmid.328767
Chicago Önal, Uğur. “Treatment of Mucormycosis With Liposomal Amphotericin B, Posaconazole and Deferasirox: A Case Report”. Journal of Microbiology and Infectious Diseases 6, no. 1 (March 2016): 32-35. https://doi.org/10.5799/jmid.328767.
EndNote Önal U (March 1, 2016) Treatment of Mucormycosis with Liposomal Amphotericin B, Posaconazole and Deferasirox: A Case Report. Journal of Microbiology and Infectious Diseases 6 1 32–35.
IEEE U. Önal, “Treatment of Mucormycosis with Liposomal Amphotericin B, Posaconazole and Deferasirox: A Case Report”, J Microbil Infect Dis, vol. 6, no. 1, pp. 32–35, 2016, doi: 10.5799/jmid.328767.
ISNAD Önal, Uğur. “Treatment of Mucormycosis With Liposomal Amphotericin B, Posaconazole and Deferasirox: A Case Report”. Journal of Microbiology and Infectious Diseases 6/1 (March 2016), 32-35. https://doi.org/10.5799/jmid.328767.
JAMA Önal U. Treatment of Mucormycosis with Liposomal Amphotericin B, Posaconazole and Deferasirox: A Case Report. J Microbil Infect Dis. 2016;6:32–35.
MLA Önal, Uğur. “Treatment of Mucormycosis With Liposomal Amphotericin B, Posaconazole and Deferasirox: A Case Report”. Journal of Microbiology and Infectious Diseases, vol. 6, no. 1, 2016, pp. 32-35, doi:10.5799/jmid.328767.
Vancouver Önal U. Treatment of Mucormycosis with Liposomal Amphotericin B, Posaconazole and Deferasirox: A Case Report. J Microbil Infect Dis. 2016;6(1):32-5.